Through the expanding usage of high throughout sequencing analysis combined with traditional cytogenetic and molecular techniques, myeloid neoplasms are becoming increasingly defined and characterized by the genetic alterations they harbor. In some instances, such as with *BCR-ABL1*, t(9;22) in chronic myelogenous leukemia (CML), the genetic alterations are considered to drive and define the disease. However, we are now beginning to realize that the genetic landscape, even within a single disease entity, can be quite complex and continues to evolve as a disease progresses, with ensuing diagnostic and therapeutic implications [@bib1], [@bib2].

Mutations of genes such as *JAK2*, *CALR* and *BCR-ABL1* are considered drivers (i.e. causative mutations which drive oncogenesis and often provide a growth advantage to cells harboring them) in the pathogenesis of myeloproliferative neoplasms (MPN) and have generally been thought to be mutually exclusive. However, there are rare reports of cases with co-occurring *BCR-ABL1*, *JAK2* and/or *CALR* mutations, suggesting a more complex picture than previously thought [@bib3], [@bib4], [@bib5]. The spectrum of mutations and the order in which they are acquired can influence the character and nature of disease progression [@bib6]. Here, we report two cases of myeloid neoplasms that exhibit genetic heterogeneity, highlighting the potential for diagnostic misinterpretation in the face of multiple disease-associated/defining mutations and emphasizes the need for thoughtful, and comprehensive genetic analysis of these neoplasms.

Patient 1. A 74-year-old woman presented in 2001 with a platelet count of 834,000/µL, normal white blood cell count (WBC), and normal hemoglobin. She underwent observation, and her platelet count continued to increase. In 2006, her WBC was 21,000/µL. Molecular testing for *JAK2* (V617F) was negative. Her first bone marrow biopsy in 2013 showed a hypercellular marrow, with granulocytic hyperplasia, increased megakaryocytes with hyperchromatic forms and marked reticulin fibrosis ([Fig. 1](#f0005){ref-type="fig"}A,B). A qualitative *BCR-ABL1* molecular assay was positive for a p190 transcript. Fluorescent in situ hybridization (FISH) and karyotype were negative for t(9;22). A diagnosis of CML was considered. Imatinib and subsequent dasatanib therapies were ineffective with no hematologic response. In 2015, the patient presented with a left breast mass, a biopsy of which showed myeloid sarcoma. FISH was positive for an 11q23 *KMT2A(MLL)* translocation. The bone marrow demonstrated acute myeloid leukemia in a background of extensive fibrosis ([Fig. 1](#f0005){ref-type="fig"}C). Genetic analysis of the bone marrow was negative for *BCR-ABL1* p190 and p210 and *KMT2A(MLL)* translocation, but was positive for both *IDH2* and *CALR* mutations. The patient received 7+3 induction chemotherapy with idarubicin, followed by decitabine and radiation therapy without a response. Her peripheral blood blast count continued to rise, and she expired 4 months after the diagnosis of AML.Fig. 1Patient 1: (A): Bone marrow biopsy from 2013 shows granulocytic hyperplasia. Megakaryocytes are increased in numbers with frequent clusters, including occasional hyperchromatic forms. (B): Reticulin stain on 2013 bone marrow biopsy shows marked fibrosis. (C): Bone marrow biopsy from 2015 shows sheets of myeloid blasts, consistent with acute myeloid leukemia. (D): Molecular analysis shows *CALR* mutant allele frequency increased over time, with appearance of *IDH2* mutation and transient *BCR-ABL1* positivity.Fig. 1

Retrospective molecular testing of the 2006 blood sample was positive for the *CALR* mutation, but wild type for *IDH2*. The initial 2013 bone marrow was positive for *BCR-ABL1*, *CALR* and *IDH2* mutations. Examination of the mutant allele frequencies over time suggests that the *CALR* was the earliest genetic event and the founder mutation of patient\'s MPN ([Fig. 1](#f0005){ref-type="fig"}D). The transiently positive *BCR-ABL1* p190, initially interpreted as evidence of CML, may have arisen in a non-dominant clone and/or one that disappeared with tyrosine kinase inhibitor therapy.

Patient 2. A 68-year-old male with presented with two year history of chronic phase CML on dasatanib. Review of his diagnostic blood and bone marrow biopsy material showed some unusual features for CML, including absolute monocytosis, lack of basophilia, and dysplastic neutrophils. The bone marrow demonstrated a predominance of myeloid progenitors and prevalent hypolobated megakaryocytes. However, occasional dysplastic megakaryocytes with nuclear separation that are often present in myelodysplastic syndromes (MDS) were also seen ([Fig. 2](#f0010){ref-type="fig"}). Molecular studies reportedly showed the presence of both a *BCR-ABL1* p210 fusion transcript and *JAK2* (p. V617F) mutation. FISH confirmed t(9;22), but cytogenetic analysis reportedly showed normal karyotype. A diagnosis of MDS/MPN was favored. Quantitative *BCR-ABL1* using PCR-based methods showed 2 copies of *BCR-ABL1* per 1000 copies of ABL1 (0.22% international scale). A targeted next generation sequencing analysis for the frequently mutated genes in myeloid neoplasms demonstrated *JAK2* (p. V617F) mutation with low allele frequency (4%); and a *SRSF2* (p. P95H) mutation with high mutant allele frequency (37%). *SRSF2* mutation has recently been described in chronic myelomonocytic leukemia (CMML), MDS, and less frequently in primary myelofibrosis [@bib7], [@bib8]. This myeloid neoplasm demonstrated a heterogeneous mixture of mutation, among which *SRSF2* had the highest mutant allele frequency, possibly representing the initiating event.Fig. 2Patient 2: (A): Rare dysplastic neutrophils are noted in the peripheral blood smear. (B): Bone marrow aspirate smear shows occasional dysplastic megakaryocytes with nuclear separation.Fig. 2

Because of the retrospective nature of this analysis, some of the historic material was not available from each patient for further testing. However, a few aspects of these cases are worth noting. The initial diagnosis of CML was understandably made in both patients based on the presence of a *BCR-ABL1* fusion. In the first case, it could be argued that the level of transcript was quite low, as it was detected by PCR methods only and not FISH or karyotype. *BCR-ABL1* fusion in the second case was detected by FISH but not karyotype. However, this case had clinical and pathologic features that are not typical for CML, including the presence of dysplasia, monocytosis, and absence of basophilia. Detection of *SRSF2* mutation, while not definitive, would further support a diagnosis of MDS/MPN in this case, were it not for the *BCR-ABL1* fusion. Even the most recent 2016 update WHO classification [@bib9] has not changed the diagnostic criteria for CML, MDS/MPN, or MPNs with regard to inclusion and exclusion of *BCR-ABL1* fusion. Given that we know, however, that low levels of *BCR-ABL1* transcript can be present in the blood of normal individuals [@bib10], it may be worth reexamining whether cases that have unusual morphologic features for CML or mutational profiles more commonly associated with other neoplasms should be more appropriately classified as a non-CML entity. On a biologic level, it is also unclear in the current cases whether the genetic abnormalities are generally present within the same clonal populations as has been described [@bib3], [@bib4], [@bib5] or separate ones exhibiting different mutations. Regardless of the initial distribution, the proportions of each mutation would theoretically be able to shift over time and/or with therapy, possibly also influenced by acquisition of additional mutations, such *IDH2* in the first case. Given this possibility, the benefit of traditional CML therapies, including tyrosine kinase inhibitors, as well as combined therapy with more recently studied treatments for MPNs, such as ruxolitinib, needs to be further investigated.

These cases provide examples of genetic heterogeneity that challenge our assumptions regarding exclusivity of driver mutations in myeloid neoplasm pathogenesis. It also highlights an important diagnostic pitfall: that *BCR-ABL1* positivity does not necessarily equate a diagnosis of CML and careful, contextual interpretation of molecular testing results is required. Lastly, these findings emphasize the need for prospective, comprehensive molecular testing in myeloid neoplasms that can potentially impact the diagnosis and therapy of patients with these diseases.
